Research analysts at Goldman Sachs Group assumed coverage on shares of Centene (NYSE:CNC) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating and a $135.00 price target on the stock. Goldman Sachs Group’s price objective would suggest a potential upside of 31.71% from the company’s current price.
A number of other analysts also recently issued reports on CNC. Cantor Fitzgerald lifted their target price on Centene to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, September 13th. Cowen reaffirmed an “outperform” rating and issued a $105.00 target price (up previously from $77.00) on shares of Centene in a research report on Wednesday, September 13th. Leerink Swann reaffirmed a “market perform” rating and issued a $90.00 target price (up previously from $78.00) on shares of Centene in a research report on Wednesday, September 13th. Deutsche Bank reissued a “buy” rating and set a $111.00 price target (up previously from $95.00) on shares of Centene in a research report on Thursday, September 14th. Finally, Zacks Investment Research raised Centene from a “hold” rating to a “buy” rating and set a $107.00 price target on the stock in a research report on Friday, September 15th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $104.21.
Centene (NYSE CNC) traded down $1.93 during trading hours on Wednesday, hitting $102.50. The company had a trading volume of 1,037,600 shares, compared to its average volume of 1,102,233. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $17,970.00, a P/E ratio of 21.18, a P/E/G ratio of 1.30 and a beta of 0.70. Centene has a twelve month low of $59.78 and a twelve month high of $105.00.
In other news, Director Robert K. Ditmore sold 4,167 shares of the business’s stock in a transaction that occurred on Thursday, October 26th. The stock was sold at an average price of $90.42, for a total transaction of $376,780.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Keith H. Williamson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $100.11, for a total value of $500,550.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 19,167 shares of company stock worth $1,864,630. Company insiders own 3.00% of the company’s stock.
Large investors have recently modified their holdings of the company. Mckinley Capital Management LLC Delaware bought a new stake in shares of Centene during the second quarter worth approximately $101,000. Baldwin Brothers Inc. MA bought a new stake in shares of Centene during the third quarter worth approximately $185,000. Sii Investments Inc. WI bought a new stake in shares of Centene during the second quarter worth approximately $202,000. Calamos Advisors LLC bought a new stake in shares of Centene during the third quarter worth approximately $207,000. Finally, Commerzbank Aktiengesellschaft FI bought a new stake in shares of Centene during the third quarter worth approximately $207,000. Institutional investors own 91.84% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/01/05/goldman-sachs-group-initiates-coverage-on-centene-cnc.html.
Centene Corporation is a healthcare company. The Company provides a portfolio of services to government sponsored healthcare programs, focusing on under-insured and uninsured individuals. The Company operates through two segments: Managed Care and Specialty Services. The Company’s Managed Care segment provides health plan coverage to individuals, through government subsidized programs, including Medicaid, the State Children’s Health Insurance Program (CHIP), Long Term Care, Foster Care, dual-eligible individuals (Duals) and the Supplemental Security Income Program, also known as the Aged, Blind or Disabled Program (ABD), Medicare, and Health Insurance Marketplace.
Receive News & Ratings for Centene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centene and related companies with MarketBeat.com's FREE daily email newsletter.